newsfilter
← Latest News
ACCESS Newswire·

Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company

Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, and Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that they have entered into a definitive merger agreement pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction.